Roche announced that its hand-held device CARDIAC point-of-care Troponin T test is available for countries accepting the CE Mark.
The test will enable healthcare workers to find out about patients with a suspected acute myocardial infarction (AMI) in 12 minutes.
Roche Diagnostics Division CEO Roland Diggelmann said: "Point-of-care diagnostics solutions play an integral role in an effective, sustainable healthcare, and their importance will further increase.
"The introduction of this improved test enables health care professionals to make earlier and more accurate interventions to save patients’ lives."
The point-of-care diagnostic system does not involve any lengthy setup procedures or sample preparation, which makes it easy to use in emergency cases.
After the test, result is determined, based on which high risk patients can be immediately sent directly to a cardiac catheterization laboratory, and patients with low risk can be sent to the hospital ward for further investigation.
The test is standardized and compatible with central lab testing, and the test can be combined with a later test using the Elecsys cardiac Troponin T high-sensitive (cTnT-hs) test.